Antibody drug conjugates
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Antibody drug conjugates
Jul 20, 2024, 10:53 |
Insight
Understanding the mechanisms underlying innate immune cell dysfunction in the TME
Alexander Ariel Padrón González, Internal Clinician at 3cert Limited, shared a post on LinkedIn about a…
Jul 12, 2024, 14:35 |
Blog
Evolving management of NSCLC - FlorezLab
FlorezLab shared on X: "The treatment landscape of advanced NSCLC is evolving! Join Dr. Narjust…
Jul 11, 2024, 06:26 |
Insight
The Role of Antibody-Drug conjugates (ADCs) in Bladder Cancer
Bladder Cancer Advocacy Network shared on X: "Get practical guidance on using antibody–drug conjugates in…
Jul 3, 2024, 08:52 |
Insight
Paolo Tarantino: More data supporting that ADCs act in part by extending the half life of payloads
Paolo Tarantino shared a post by Raffaele Colombo on X, adding the following: “More data…
Jun 28, 2024, 06:15 |
Blog
The American Journal of Managed Care highlights the latest research from Erika Hamilton
Sarah Cannon Research Institute shared the following post on LinkedIn: “AJMC - The American Journal…
Jun 28, 2024, 01:53 |
Blog
Julia Lai-Kwon: Hope Rugo highlighting the different toxicities between different ADCs
Julia Lai-Kwon, Medical Oncologist and PhD candidate at Peter Mac Cancer Centre, recently shared a…
Jun 25, 2024, 16:01 |
Insight
Paolo Tarantino: Phase 1 trial of the HER2 topo1 ADC SHR-A1811 out in Journal of Clinical Oncology
Paolo Tarantino shared on X: . "Phase 1 trial of the HER2 topo1 ADC SHR-A1811…
Jun 24, 2024, 13:33 |
Blog
Erika Hamilton's insights into the future of ADCs in oncology - Sarah Cannon Research Institute
Sarah Cannon Research Institute shared the following post on LinkedIn: “We are thrilled to share…
Jun 11, 2024, 12:56 |
Insight
Radiopharmaceuticals are revolutionizing the way we approach diagnosis, medical treatment, and patient care - Allucent
Allucent recently shared a post on LinkedIn: "Radiopharmaceuticals are gaining significant attention as this treatment…
Jun 11, 2024, 11:49 |
Blog
Cristian Massacesi: Very much enjoyed being part of the Endpoints panel at ASCO2024
Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer at AstraZeneca, posted on LinkedIn:…
Jun 9, 2024, 09:45 |
Societies
Chandler Park: A fun discussion at ASCO24 with David O’Malley
Chandler Park recently shared on X: "Dr. David O’Malley and I have a fun discussion…
Jun 8, 2024, 06:47 |
Blog
ArriVent and Alphamab Partner in $615.5 million collaboration for Novel ADC Cancer Treatments - GeneOnline
GeneOnline shared a post on LinkedIn: “ArriVent BioPharma and Alphamab Oncology announce a $615.5 million…
Jun 3, 2024, 12:38 |
Insight
Ahmad Sufian Ab Rahman: Delighted to share the work with Western Australia medical oncologists and clinical trials teams at Linear Clinical Research at ASCO
Ahmad Sufian Ab Rahman, Consultant Medical Oncologist at Cancer CRI Centre, shared on LinkedIn: …
May 29, 2024, 08:36 |
Insight
A new review summarizing the different antibody-based approaches for targeting cancer cells - Nature Reviews Cancer
Nature Reviews Cancer shared a post on X: "Don´t miss this review summarizing the different…
May 22, 2024, 04:28 |
Blog
Michael Torres: This review is getting a lot of play
Michael Torres, PhD in Cancer Bio at UT Southwestern News, shared on X/Twitter: "Homogeneous multi-payload…
May 16, 2024, 09:40 |
Blog
Yale Cancer Center - Dr. Patricia LoRusso will be presenting at ESMO Breast
Yale Cancer Center shared a post on X: "Thursday at 9:10am EST, Dr. Patricia LoRusso will…
May 13, 2024, 14:12 |
Blog
Raffaele Colombo: Personal selection of 30 new ADCs that will be presented at ASCO24
Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared on X: "Personal selection of…
May 6, 2024, 19:10 |
Blog
Erman Akkus: ASCO Ed book on mNSCLC without oncogenic alterations
Erman Akkus, medical oncologist at Ankara Medical University, shared on Twitter/X: "Metastatic NSCLC without oncogenic…
Apr 29, 2024, 20:00 |
Opinion
Erika Hamilton: Really feel like we don't need to be testing for HER-2 for TDXd in breast cancer
Erika Hamilton shared a post by Giuseppe Curigliano, Chief of the Clinical Division of Early…
Apr 29, 2024, 10:43 |
Blog
Stephanie Graff: Getting excited for ASCO24. Abstract titles are officially out
Stephanie Graff shared a post on X: "Getting excited for ASCO24 Annual Meeting. Abstract titles are…
Apr 26, 2024, 17:44 |
Drugs
Paolo Tarantino: The agnostic potential of Antibody Drug Conjugates with Roberto Carmagnani Pestana, MD is among the most cited of 2022-2023 on CA - A Cancer Journal for Clinicians
Apr 26, 2024, 11:05 |
Blog
Paolo Tarantino: Wonderful experience to brainstorm about the agnostic potential of ADCs with Roberto Carmagnani Pestana
Paolo Tarantino, Research Fellow at Dana Farber Cancer Institute, shared a post by Roberto Carmagnani Pestana,…
Apr 13, 2024, 14:18 |
Insight
Jonathan Cohen discusses hepatocellular carcinoma at the annual meeting of the Israeli Oncology Society
Jonathan Cohen, Director of Clinical Research at Sharett Institute of Oncology of Hadassah Medical Center,…
Apr 11, 2024, 08:13 |
Drugs
Tom Powles: Disitimab, Vedotin and Pembrolizumab vs chemotherapy with or without Avelumab in advanced Urothelial Carcinoma
Tom Powles, Director of Barts Cancer Center, recently shared on X: “Trial in progress: The…
Mar 16, 2024, 15:30 |
Blog
Narjust Florez: I spy a visitor in the thoracic oncology hallway Dr. Paolo Tarantino
Quoting Narjust Florez on X/Twitter: "I spy a visitor in the thoracic oncology hallway Dr.…
Feb 1, 2024, 15:19 |
Opinion
Paolo Tarantino: Nectin4 amplification predicts response to enfortumab vedotin in metastatic urothelial carcinoma
Paolo Tarantino, Medical Oncologist and Research Fellow at the Dana-Farber Cancer Institute, shared by Niklas…
Jan 20, 2024, 16:26 |
Insight
Raju Joshi: Some takeaways from JPM 2024
Quoting Raju Joshi, Chief Executive Officer and Founder in Clinical Partners Group, on LinkedIn: ''JPM…
Jan 12, 2024, 21:53 |
Opinion
Yüksel Ürün: Exploring the next generation of antibody–drug conjugates
Yüksel Ürün, Professor at the Department of Medical Oncology, Ankara University School of Medicine, recently…
Dec 15, 2023, 06:38 |
Blog
Jason Mouabbi: Our recent MD Anderson Cancer Center publication addresses a pivotal question
Jason Mouabbi, Breast Medical Oncologist at the MD Anderson Cancer Centre, shared on X/Twitter: "Exciting…
Nov 5, 2023, 18:42 |
Blog
A strategic collaboration with Jiangsu Hengrui Pharmaceuticals and EMD Serono
EMD Serono posted on LinkedIn. "News: Today we entered a strategic collaboration with Jiangsu Hengrui Pharmaceuticals. This…
Oct 31, 2023, 10:11 |
Blog
Yao Yu: Happy to share our work on Stereotactic radiosurgery with concurrent Antibody Drug Conjugates
Yao Yu, Radiation Oncologist at Memorial Sloan Kettering Cancer Center, shared on X/Twitter: "Happy to…
Oct 2, 2023, 22:37 |
Insight
Paolo Tarantino: Antibody drug conjugates (ADCs) are leading to relevant survival improvements for multiple types of cancer.
Paolo Tarantino, MD and researcher at the European Institute of Oncology and clinical research fellow…
All:
32
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube